Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.34 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including oligodendrocytes; strongest in late spermatids | 0.75 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 0926
Sealed predictions
- IPO13 in dopamine neurons, braak-0.02 (p 0.964) → -0.03 (p 0.946)receipt 0934
- IPO13 in oligodendrocytes, braak-0.38 (p 0.311) → +0.42 (p 0.262)receipt 0933
Swarm cases
receipt 0934: IPO13 in dopamine neurons, braak
- power
- full sample -0.02 (p 0.928, n 18), 95% CI -0.48 to +0.45. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.02 (p 0.928, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.00 (p 0.990, n 18). could be the mix.
- skeptic
- leave-one-out range -0.15 to +0.10, sign flips 6; without severely affected donors -0.02 (p 0.928, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for IPO13 in dopamine neurons.
case closed: nothing better to follow up.
receipt 0933: IPO13 in oligodendrocytes, braak
- power
- full sample -0.03 (p 0.894, n 18), 95% CI -0.49 to +0.44. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.05 (p 0.847, n 18). does not hold up.
- composition
- oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.02 (p 0.942, n 18). could be the mix.
- skeptic
- leave-one-out range -0.16 to +0.08, sign flips 6; without severely affected donors -0.03 (p 0.894, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for IPO13 in oligodendrocytes.
case closed: nothing better to follow up.
Receipts
loading the receipts